收评：创业板指低开低走跌1.91% 全市场超3800只个股下跌 智通财经5月15日电，市场全天震荡调整，创业板指领跌。沪深两市全天成交额1.15万亿，较上个交易日缩量1643亿。盘面上，市场热点较为杂乱，个股跌 多涨少，全市场超3800只个股下跌。从板块来看，合成生物概念股逆势大涨，金达威等多股涨停。食品等消费股一度反弹，西王食品涨停。ST板块再度走 强，*ST建艺等20余股涨停。下跌方面，算力概念股展开调整，宏景科技跌近10%。板块方面，合成生物、食品、ST板块、港口等板块涨幅居前，软件开 发、跨境支付、算力、鸿蒙概念等板块跌幅居前。截至收盘，沪指跌0.68%，深成指跌1.62%，创业板指跌1.91%。 | 上证指数 | | 深证成指 | 创业板指 | | --- | --- | --- | --- | | -3380.82 | | -10186.45 | -2043.25 | | -23.13 | -0.68% | -167.77 -1.62% | -39.9 -1.92 | | THE LEAST OF A LEASE OF A BEACH AND AN | 2 / 1 / 1 | | | 浙停表现 封 ...

Market Overview - On May 15, A-shares experienced a decline, with the Shanghai Composite Index falling by 0.42% to 3389.75 points, the Shenzhen Component Index down by 1.12%, and the ChiNext Index decreasing by 1.35% [1][2] - The total trading volume for A-shares reached 765.59 billion yuan [1] Economic Indicators - The People's Bank of China conducted a 645 billion yuan reverse repurchase operation with a fixed interest rate of 1.40%, resulting in a net withdrawal of 219.1 billion yuan for the day [2] Industry Insights - The China-U.S. Economic and Trade Cooperation Exchange Conference was successfully held in Washington, emphasizing the long-standing and mutually beneficial trade relationship between the two countries [3] - Despite current challenges, there is significant potential for future cooperation, particularly in maintaining global supply chain stability [3] Sector Performance - Port and shipping stocks saw a resurgence, with notable increases in shares of Nanjing Port, Lianyungang, and Ningbo Maritime [3] - Beauty and personal care stocks also performed well, with companies like Jieya Co. and Furuida reaching their daily limit up [3] - Synthetic biology stocks were active, with companies such as Chuaning Biological, Jindawei, and Hainan Haiya hitting their daily limit up [3] Sector Trends - The synthetic biology sector is expected to grow, with significant applications in various fields, although it currently holds a limited share in the overall chemical market [4] - The international landscape for synthetic biology is primarily dominated by the U.S. and Europe, which may influence domestic policy and development [4] Company Profiles 1. **Chuaning Biological**: Focuses on synthetic biology with products in production and plans to expand into high-value products and efficient strains by 2025 [7] 2. **Jieya Co.**: A leading manufacturer of wet wipes, shifting focus towards wet toilet paper and expanding into medical devices and cosmetics [8] 3. **Furuida**: Aims to build a comprehensive health industry chain, leveraging R&D strengths in cosmetics and pharmaceuticals [8] 4. **Jindawei**: Positioned as a leader in the health supplement market, benefiting from market expansion and stable financial performance [8]

Core Viewpoint - The A-share market experienced a decline, with the ChiNext Index falling by 1.35%, while the shipping sector continued to show strong performance [1] Market Performance - The three major indices opened lower and continued to decline, with the Shanghai Composite Index down by 0.42%, the Shenzhen Component Index down by 1.12%, and the ChiNext Index down by 1.35% [1] - The daily chemical sector showed resilience, with companies like Jieya Co. and Lafang Home Care reaching the daily limit [1] - The synthetic biology concept also saw gains, with Chuaning Biological and Jindawei hitting the daily limit [1] - The shipping sector maintained its strong momentum, with Ningbo Shipping, Ningbo Ocean, and Nanjing Port all reaching the daily limit [1] - The ST sector was active, with over 20 stocks such as *ST Nanzhi and *ST Aowei hitting the daily limit [1] - The pet economy concept rose, with Meino Biological and Ruoyu Chen reaching the daily limit [1] Sector Performance - The daily chemical, coal, food and beverage, and agriculture sectors led in gains [1] - Conversely, the software services, engineering machinery, diversified finance, and communication equipment sectors experienced the largest declines [1] - Weak performance was noted in sectors such as digital currency, AI, military trade concepts, and computing power leasing [1]

Market Overview - A-shares opened lower with the Shanghai Composite Index down 0.16%, Shenzhen Component down 0.28%, and ChiNext down 0.34% [1] - The People's Bank of China announced a 0.5 percentage point reduction in the reserve requirement ratio for financial institutions, expected to provide approximately 1 trillion yuan in long-term liquidity [1] Shipping Sector - The shipping sector continued to show strength, with stocks like Ningbo Shipping, Nanjing Port, and Ningbo Ocean hitting the daily limit [2] - Following a significant reduction in bilateral tariffs between China and the U.S., export dynamics have changed, leading to an increase in shipping rates, particularly on the U.S. West Coast, which saw a 10.2% rise in the Shanghai Export Container Freight Index [2] Coal Sector - The coal sector strengthened, with Daya Energy hitting the daily limit and other companies like Yunmei Energy and Liaoning Energy showing notable gains [3] Military Industry - Military stocks surged, with Chengfei Integration achieving its seventh consecutive daily limit, and other companies like Andavil and Tongda Co. also hitting the limit [4] - Chengfei Integration reported that its main business is focused on automotive parts and tooling, with a 96.91% revenue share, while its aerospace parts business accounts for only 1.74% [4]

Core Viewpoint - Synthetic biology concept stocks are experiencing significant upward movement, with notable gains in several companies [1] Group 1: Company Performance - Chuaning Biological (301301) reached a 20% daily limit increase [1] - Bawi Co., Ltd. saw an increase of over 20% [1] - Toxin Pharmaceutical (301089) rose by more than 10% [1] - Jindawei (002626), Oukang Pharmaceutical, and Weilan Biological (603739) also experienced upward trends [1] Group 2: Market Activity - There is a notable influx of dark pool funds into these stocks [1]

Core Insights - The article highlights the establishment and growth of Zhongke Arno Biotechnology Co., Ltd., which has become a model for synthetic biology manufacturing in China, particularly in the Guangming Science City [1][3] Company Overview - Zhongke Arno has developed a 3,300 square meter vertical factory that integrates research, production, and sales, representing the largest synthetic biological reactor in Guangming District [1][3] - The company has achieved the first and only production license for naked algae products in China since the material was included in the national new food raw material directory in 2013, and has successfully entered mass production [3] Industry Context - The company operates in the synthetic biology sector, focusing on high-value biological active substances and biomedical materials, particularly in areas such as anti-aging, anti-tumor, and immune enhancement [3] - The establishment of the company aligns with national strategic priorities, contributing to the self-sufficiency of China's high-end biological manufacturing supply chain by achieving import substitution in multiple fields [3] Entrepreneurial Journey - The founder, Chen Yang, transitioned from academia to entrepreneurship, motivated by the rapid growth of synthetic biology enterprises in Shenzhen and the supportive environment for innovation in Guangming Science City [2][4] - The company emphasizes a flexible employment and entrepreneurship support platform called "Smart Mulan," aimed at empowering more women in technology [4] Team Composition - The company boasts a young team with an average age in the 30s, comprising 77% research and development personnel and 91% with high academic qualifications, positioning itself to compete with leading global enterprises [4]

业绩持续下滑的深层动因 2024年，华恒生物净利润大幅缩水的主因在于缬氨酸产品的价格压力。公司明确表示，"2024年市场缬 氨酸产品价格处于历史低位"，且"市场竞争加剧"导致该产品价格及毛利率同比显著下降。作为氨基酸 系列的核心品类之一，缬氨酸的价格波动直接冲击了公司利润空间。此外，经营规模扩大带来的费用增 加进一步侵蚀利润，2024年相关费用较去年同期明显攀升。 作为合成生物领域的龙头企业，华恒生物近年来的业绩表现与股价走势引发市场高度关注。2024年，公 司营业收入虽同比增长12.37%至21.78亿元，但归母净利润同比暴跌57.80%至1.9亿元，扣非净利润下滑 59.54%至1.77亿元。2025年一季度，其营收增长37.20%至6.87亿元，但归母净利润同比下降40.98%至 5109.61万元，连续四个季度呈现负增长态势。面对市场竞争加剧与核心产品价格承压的双重挑战，华 恒生物正通过高管团队调整与技术布局寻求突围。 2025年一季度，尽管销售规模扩大推动营收增长，但净利润下滑趋势仍未扭转。公司解释称，"缬氨酸 产品价格及毛利率较去年同期下降"是核心影响因素。若行业竞争格局维持现状或进一步恶化，华恒 ...

Core Insights - Shenzhen has introduced new legislation aimed at promoting the innovation and development of the synthetic biology industry, addressing key challenges such as supply chain coordination and long approval cycles for new materials [1][5]. Group 1: Legislative Developments - The draft regulations consist of 30 articles and aim to tackle common pain points in the synthetic biology industry, including supply chain issues and the lengthy approval process for new materials [1]. - The regulations will be open for public consultation until June 13, indicating a collaborative approach to policy-making [1]. Group 2: Market Potential - According to McKinsey, the global bioeconomy is projected to reach $2 trillion to $4 trillion in the next 10-20 years, with the contribution of biological modification expected to rise to 30%-70% over time [1][4]. - In China, 40% of newly established synthetic biology companies in the past three years are concentrated in Shenzhen, highlighting the city's growing significance in this sector [1][5]. Group 3: Industry Collaboration - The draft regulations emphasize collaboration with national and provincial health departments to enhance the safety assessment of new food materials and additives [3]. - The regulations also aim to improve the efficiency of the approval process for new cosmetic ingredients, addressing existing challenges such as high costs and long timelines [2][3]. Group 4: Support Mechanisms - Shenzhen plans to establish specialized industrial parks for synthetic biology, providing necessary R&D and production facilities, as well as public technical services [5][6]. - The city will support higher education institutions in offering programs related to synthetic biology and encourage partnerships between academia and industry to cultivate talent [5][6]. Group 5: Financial Initiatives - The Shenzhen government will leverage investment funds to support small and medium-sized enterprises in the synthetic biology sector, enhancing access to financing for startups [6]. - A private equity fund focused on synthetic biology was established in Shenzhen with a scale of 1.5 billion yuan, and local banks have increased credit limits for startups in this field [6].

Core Viewpoint - The article highlights the significance of the New Fortune Gold Medal Secretary selection in the Chinese capital market, emphasizing the role of outstanding secretaries in enhancing corporate governance and investor relations, thus contributing to high-quality market development [1]. Company Overview - Jinbo Biological was established in 2008 and is headquartered in Taiyuan, Shanxi. It is recognized as a national-level specialized and innovative "little giant" enterprise and a key player in the synthetic biology industry chain in Shanxi Province. The company focuses on the research and industrialization of recombinant humanized collagen [5]. Key Achievements - Jinbo Biological became the first A-share listed company in China centered on "recombinant humanized collagen" after successfully completing its listing on July 20, 2023, on the Beijing Stock Exchange. This milestone serves as a model for the industrialization of original achievements by small and medium-sized enterprises in China [3]. - The company has received multiple approvals for innovative medical devices, including the first medical device product in China using new biological materials, and has established itself as a leader in the production of implant-grade medical devices globally [6][7]. Technological Breakthroughs - Jinbo Biological has achieved three core technological breakthroughs: 1. Safety breakthrough with a protein amino acid sequence highly consistent with natural collagen, showing strong biocompatibility and no immunogenic issues in over 2 million clinical applications [8]. 2. Effectiveness breakthrough with a clear 164.88° flexible triple helix structure, recognized by the international protein database [8]. 3. Application scenario breakthrough with high cell adhesion surpassing natural collagen, demonstrating excellent tissue repair characteristics across various fields [8]. Innovation Strategy - The company adheres to an "original innovation" strategy, having established six major technology platforms and multiple joint research platforms with prestigious institutions, covering the entire chain from basic research to clinical transformation and industrial implementation [9]. Role of the Secretary - The role of the board secretary is crucial in bridging the company and the capital market, requiring solid financial and legal knowledge, as well as excellent communication and coordination skills. The secretary's responsibilities include ensuring compliance, enhancing communication with regulatory bodies, investors, and media, and fostering a transparent public relations environment [14].

□ 本报记者徐维庆通讯员周健 "中试完成后，成品推向市场的成功率可达九成。"近日，站在已建成的全省最大合成生物蛋白制造中试 平台前，江苏创健医疗科技股份有限公司董事长钱松对合成生物的未来激情满满。 中间性试验，即小型生产模拟试验，是产品大规模量产前必不可少的环节。合成生物的中试，对相关企 业产品加速投向未来市场有着决定性作用。创健医疗投资1.2亿元，耗时两年时间打造了华东地区最大 的合成生物蛋白制造中试平台，集成陶瓷膜过滤、超滤、纳滤等多套纯化设备，实现酵母、大肠杆菌等 微生物发酵工艺开发与放大，同时结合AI实现全智能化生物制造，采用西门子自动化控制系统精准控 制工艺参数，每年可完成100—200批次工艺验证。 目前，创健医疗的中试平台已经开始承载核酸四面体、重组胶原蛋白等前沿项目工艺验证；同时，北京 市昌平合成生物制造技术创新中心、江南大学等高校科研院所与创健医疗联手，在常州启用部分先期科 研成果的中试，完成后将在全国范围内推广新品。 创健医疗在合成生物领域加码中试战略布局，有着更深层次的考量。以治疗阿尔茨海默病为例，在新药 开发中，基于DNA折纸技术构建，由4条单链DNA通过碱基互补配对原则，自发组装形成 ...